BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...company AgBiome this week to develop novel RNA-guided...
...health and diagnostics. COMPANY PROFILELifeEDIT Therapeutics Durham, N.C.Technology: novel RNA-guided...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...whether and how they cut DNA or RNA...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

...Simone Fishburn: And just for our audience to clarify the Pfizer, BioNTech vaccine is an RNA...
...there, can that be shipped at room temperature?[00:06:01] Mene Pangalos: So again, I think the RNA...
...actually is it's a self amplifying RNA is relatively inexpensive.[00:06:15] But as you say, there RNA...
BioCentury | Nov 12, 2020
Management Tracks

ObsEva, Korro bring in new CEOs; plus Cerebral, Spartan, Apnimed and Micronoma

...to serve as a board member. O’Callaghan was CEO of Petra Pharma Corp. Ram Aiyar joined RNA...
BioCentury | Nov 10, 2020
Product Development

New bar set by BioNTech, Pfizer COVID-19 vaccine could see swift influx of challengers

...Scrutiny will be particularly rigorous for other RNA...
...42% of which they said had diverse backgrounds.RNA...
BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

...RNA promotes insulin releaseAn article in Nature Communications has implicated in diabetes reduced levels of a circular RNA...
...RNA than islets from non-diabetics; and showed in normal rat islets that silencing the circular RNA decreased...
BioCentury | Nov 2, 2020
Product Development

Next-generation checkpoints take another hit as Jounce stops enrollment in ICOS agonist trial

...Phase II SELECT study, which is evaluating vopratelimab plus PD-1 inhibitor JTX-4041 in patients with an RNA...
BioCentury | Oct 31, 2020
Finance

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...antiviral to treat COVID-19 patients outside the hospital setting. The purine nucleotide prodrug, which targets RNA...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...nearly two-year tenure include a partnership with RNA...
...Accent Therapeutics Inc. to develop therapies targeting RNA-modifying...
...You can start with chromatin remodeling, or RNA...
BioCentury | Oct 27, 2020
Distillery Therapeutics

Peptide-based SARS-CoV-2 3CLpro inhibitor identified for COVID-19

...to detect SARS-CoV-2 3CLpro in seven patients positive for SARS-CoV-2 RNA, and not in four RNA-negative...
Items per page:
1 - 10 of 5528